Welcome to our dedicated page for Theralase Technologies news (Ticker: TLTFF), a resource for investors and traders seeking the latest updates and insights on Theralase Technologies stock.
Theralase Technologies Inc. (TLTFF) is a clinical stage pharmaceutical company whose news flow centers on the development of light, radiation, sound and drug-activated small molecule compounds for the destruction of cancers, bacteria and viruses. Company announcements frequently highlight progress in its oncology and antiviral programs, financing activities and collaborations with partners.
Investors following TLTFF news can expect regular updates on Theralase’s Phase II clinical study in Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer carcinoma in situ, where the company is clinically investigating light-activated Ruvidar. Releases have included interim clinical response data, enrollment status and timelines for data lock and regulatory submissions as described by the company.
News items also cover preclinical research, such as studies of radiation-activated Rutherrin in multiple cancer models and peer-reviewed data on Ruvidar as an antiviral candidate against Herpes Simplex Virus Type 1. These updates summarize scientific findings, mechanisms under investigation and potential implications for future development, as presented by Theralase and collaborating researchers.
From a capital markets perspective, Theralase’s news includes details of non-brokered private placements, warrant extensions and short-term loans, along with the intended use of proceeds for clinical studies, development work and working capital. The company also issues reminders and summaries for investor conference calls where management discusses financial statements and operational milestones.
This TLTFF news page aggregates these disclosures so readers can review company-stated clinical, scientific and financing developments in one place and monitor how Theralase describes the evolution of its small molecule programs over time.
Theralase Technologies (OTCQB: TLTFF), a clinical stage pharmaceutical company, has released its Q2 2025 financial results showing mixed performance. The company reported a 12% revenue increase to $310,933 and a 47% gross margin improvement to $131,967 for the six-month period ended June 30, 2025.
The company completed three private placements raising total gross proceeds of approximately $1.66 million. In its Study II clinical trial, 86 patients (96% of target) have been treated, with 61.4% achieving Complete Response and 70% achieving Total Response. At the 450-day assessment, 39.5% of patients maintained Complete Response, demonstrating treatment durability.
Theralase Technologies (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on light, radiation, sound and drug-activated therapeutics, has completed a non-brokered private placement. The company raised CAD $672,627 by issuing 3,363,134 units at CAD $0.20 per unit.
Each unit comprises one common share and one warrant, with warrants exercisable at CAD $0.30 for 5 years. The proceeds will support the ongoing Phase II Non-Muscle Invasive Bladder Cancer (NMIBC) clinical study, Rutherrin® development, and working capital needs. Notably, 130,000 units were issued to company insiders, representing CAD $26,000 of the total raise.
Theralase Technologies (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on light, radiation, sound and drug-activated therapeutics for treating cancer, bacteria and viruses, has announced plans to extend the expiry date of 4.8 million share purchase warrants. The warrants, originally issued on June 30th, 2023, will be extended from June 30th, 2025, to June 30th, 2028.
The warrants remain exercisable at CAN $0.35 per share, with all other terms and conditions unchanged. This extension is pending final acceptance from the TSX Venture Exchange.
Theralase Technologies (TLTFF) announced it will present new preclinical research on radiation-activated Rutherrin® at the ASTRO 2025 67th Annual Meeting in San Francisco. The study evaluates Rutherrin®, a ruthenium-based drug formulated with human transferrin, against radiation alone in treating cancer.
The research explores Rutherrin's dual cancer-fighting mechanism: immediate cytotoxicity through Reactive Oxygen Species generation and sustained immune response through Immunogenic Cell Death. Key aspects to be presented include tumor targeting, blood-brain barrier penetration, survival rates, and resistance inhibition.
The company plans to complete GLP toxicology studies in 2025 and aims to launch clinical studies in early 2026 targeting multiple cancers including GBM, lung, pancreatic, lymphoma, and colorectal cancers.
Theralase Technologies (TLTFF) has announced groundbreaking preclinical results showing that their radiation-activated Rutherrin® treatment is 100 times more effective at destroying cancer cells compared to radiation therapy alone. The company will present these findings at the ASTRO 2025 conference in San Francisco.
Key findings demonstrate that Rutherrin®, a ruthenium-based small molecule drug, shows selective tumor targeting, enhanced blood-brain barrier penetration with 10x higher concentrations in GBM tumors, and combines direct tumor cell destruction with immune activation. The treatment works through Radio Dynamic Therapy (RDT), generating Reactive Oxygen Species for immediate cytotoxicity and Immunogenic Cell Death for durable immune response.
The company plans to complete GLP toxicology studies in 2025 and launch clinical studies in early 2026, targeting GBM, lung, pancreatic, lymphoma, and colorectal cancers.